» Articles » PMID: 28493008

Role of Family History and Tumor Location on Prognosis of Patients with Colorectal Cancer and Synchronous Metastases

Overview
Date 2017 May 12
PMID 28493008
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Family history of colorectal cancer and tumor location along colon-rectum have been reported as prognostic factors. The aim of the current study is to analyze the role of both on overall survival in a series of patients with metastatic colorectal cancer with synchronous metastases.

Methods: A retrospective mono-institutional analysis has been performed on patients, who received chemotherapy from 2004 to 2008. A Cox proportional-hazards regression was used to calculate hazard ratio (HR) for death, after adjustment for other variables (tumor metastasectomy, number of organs involved with metastases, number of anti-neoplastic drugs, age, sex, tumor grade, baseline CEA).

Results: Two hundred and seven patients were included in the study. Only tumor metastasectomy was related with a better overall survival (HR 4.995; P < 0.001), whereas a positive family history was associated with a poor prognosis (HR 0.386; P = 0.021). After exclusion of rectal tumors, the negative prognostic effect of a positive family history appeared limited to patients with a left-sided colon cancer (HR 0.183; P = 0.036).

Conclusion: Family history for colorectal cancer in a first-degree relative, and not tumor location, has a significant relationship with the prognosis of patients with a colorectal cancer and synchronous metastases.

Citing Articles

[Screening of serum oxysterol biomarkers for colon cancer by liquid chromatography-tandem mass spectrometry].

Ma Z, Li Z, Wang H, Wang R, Han X Se Pu. 2022; 40(6):541-546.

PMID: 35616199 PMC: 9404029. DOI: 10.3724/SP.J.1123.2022.01001.


Therapeutic Effect and Prognosis of Biliary Tract Tumor Transformation.

Shang P, Yu Y, Yan P, Xu H Comput Math Methods Med. 2022; 2022:9489003.

PMID: 35547567 PMC: 9085330. DOI: 10.1155/2022/9489003.


27-hydroxycholesterol decreases cell proliferation in colon cancer cell lines.

Warns J, Marwarha G, Freking N, Ghribi O Biochimie. 2018; 153:171-180.

PMID: 30009860 PMC: 6390838. DOI: 10.1016/j.biochi.2018.07.006.

References
1.
Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F . Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2016; 3(2):194-201. PMC: 7505121. DOI: 10.1001/jamaoncol.2016.3797. View

2.
Schiemann U, Muller-Koch Y, Gross M, Daum J, Lohse P, Baretton G . Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features. Digestion. 2004; 69(3):166-76. DOI: 10.1159/000078223. View

3.
Hemminki K, Sundquist J, Brandt A . Familial mortality and familial incidence in cancer. J Clin Oncol. 2011; 29(6):712-8. DOI: 10.1200/JCO.2010.30.5664. View

4.
Lu K, Wood M, Daniels M, Burke C, Ford J, Kauff N . American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014; 32(8):833-40. PMC: 3940540. DOI: 10.1200/JCO.2013.50.9257. View

5.
Samowitz W, Sweeney C, Herrick J, Albertsen H, Levin T, Murtaugh M . Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14):6063-9. DOI: 10.1158/0008-5472.CAN-05-0404. View